Terazosin
CLINICAL USE
Alpha-adrenoceptor blocker:Hypertension Benign prostatic hyperplasia (BPH)
DOSE IN NORMAL RENAL FUNCTION
Hypertension: 1–20 mg once daily BPH: 1–10 mg once daily
PHARMACOKINETICS
Molecular weight :459.9 %Protein binding :90–94 %Excreted unchanged in urine : 10 Volume of distribution (L/kg) :0.5–0.9half-life – normal/ESRD (hrs) :9–12/Unchanged DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
20 to 50 : Dose as in normal renal function 10 to 20 : Dose as in normal renal function <10 : Dose as in normal renal function DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD :Not dialysed. Dose as in normal renal function HD :Not dialysed. Dose as in normal renal functionHDF/high flux :Unknown dialysability. Dose as in normal renal functionCAV/VVHD :Unknown dialysability. Dose as in normal renal function IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugs Anaesthetics: enhanced hypotensive effect Antidepressants: enhanced hypotensive effect with MAOIsBeta-blockers: enhanced hypotensive effect; increased risk of first dose hypotensive effect Calcium-channel blockers: enhanced hypotensive effect; increased risk of first dose hypotensive effect Diuretics: enhanced hypotensive effect; increased risk of first dose hypotensive effect Moxisylyte: possibly severe postural hypotension when used in combination Vardenafil, sildenafil and tadalafil: enhanced hypotensive effect – avoid concomitant use ADMINISTRATION
Reconstition
– Route
Oral Rate of Administration
–Comments
– OTHER INFORMATION
Therapy should be initiated with a single dose of 1 mg given at bedtime.
See how to identify renal failure stages according to GFR calculation
See how to diagnose irreversible renal disease
Home